Lonza expects to begin mass production of Moderna’s COVID-19 vaccine in December

Lonza, the Swiss company tasked with mass production of Moderna’s COVID-19 vaccine, expects the first batches for widespread public use to go out in December. Interim CEO and Chairman Albert Baehny tells CNNMoney that the vaccine will initially be made in the U.S., with a production line in Switzerland also planned. Lonza’s stock surged Monday after Moderna reported positive early results from a Phase 1 clinical trial, which focuses on whether a vaccine is safe and elicits an immune response. The Food and Drug Administration has cleared the U.S. biotech company to begin Phase 2 trials, which typically involve several hundred of people, and Moderna plans to start large-scale clinical trials in July.

Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem?

Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet.

© 2020 CNNMoney Switzerland SA. All Rights Reserved. Terms under which this service is provided to you.

To Top